
CoStim
CoStim developed novel biologics targeting immune checkpoint inhibitors for oncology indications. CoStim was acquired by Novartis in 2014.
CoStim developed novel biologics targeting immune checkpoint inhibitors for oncology indications. CoStim was acquired by Novartis in 2014.